title: Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux.
abstract: Using ranirestat, an aldose reductase (AR) inhibitor, we investigated the relationship between sorbitol and fructose levels in the sciatic nerve and motor nerve conduction velocity (MNCV) in streptozotocin (STZ)-treated diabetic rats. Ranirestat inhibited rat and recombinant human AR with similar IC50 values and equipotently prevented sorbitol accumulation in rat erythrocytes and sciatic nerves in vitro. One week after STZ administration, sorbitol levels in rat erythrocytes and sciatic nerves significantly increased while MNCV decreased. Oral administration of ranirestat (0.03-1.0 mg/kg per day) for 3 weeks dose-dependently decreased the elevated sorbitol and fructose levels in the rat sciatic nerves without affecting blood glucose level. Particularly, at doses of 0.1 mg/kg per day or higher, ranirestat normalized both sorbitol and fructose levels in the sciatic nerves of STZ-treated rats. Ranirestat (0.1-1.0 mg/kg per day) also improved the STZ-induced decrease in MNCV in a dose-dependent manner. This improvement correlated with the decrease of sorbitol and fructose levels in the rat sciatic nerves. These findings indicate that ranirestat improves MNCV via normalization of sorbitol and fructose accumulation in the sciatic nerve.
authors.affiliation: Pharmacology Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Japan. takafumi-matsumoto@ds-pharma.co.jp
authors.forename: Takafumi
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Ono
authors.forename: Masuo
authors.initials: M
authors.lastname: Kurono
authors.forename: Akemi
authors.initials: A
authors.lastname: Kuromiya
authors.forename: Keiji
authors.initials: K
authors.lastname: Nakamura
authors.forename: Vera
authors.initials: V
authors.lastname: Bril
mesh_terms: D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism / Q000503:physiopathology*; D004912:Erythrocytes / Q000378:metabolism; D005632:Fructose / Q000378:metabolism; D066298:In Vitro Techniques; D008297:Male; D009431:Neural Conduction / Q000187:drug effects*; D011719:Pyrazines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D012584:Sciatic Nerve / Q000187:drug effects / Q000378:metabolism; D013012:Sorbitol / Q000378:metabolism; D013141:Spiro Compounds / Q000494:pharmacology*
chemical_list: D011719:Pyrazines; D013141:Spiro Compounds; D005632:Fructose; D013012:Sorbitol; D000449:Aldehyde Reductase; C115070:ranirestat